Clinical Trials on Ovarian Seromucinous Carcinoma

Total 25633 results

Sohag University

Recruiting

Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma

Ovarian Carcinoma

Egypt
Dana-Farber Cancer Institute

Recruiting

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Ovarian Cancer | Endometrial Cancer | Ovarian Carcinoma | Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Ovarian Cancer Stage 3 | Endometrial Cancer Stage

United States
Dana-Farber Cancer Institute
Celula, Inc.

Terminated

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
Burzynski Research Institute

Terminated

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
Daiichi Sankyo, Inc.

Completed

Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer

Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV

United States
University Health Network, Toronto

Completed

A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer

Platinum-resistant Epithelial Ovarian Cancer

Canada
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Active, not recruiting

Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer (GOGER-01)

Ovarian Cancer | Fallopian Tube Carcinoma | Peritoneal Carcinoma

Italy
NYU Langone Health
GlaxoSmithKline

Withdrawn

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

Ovarian Carcinoma

United States
National Taiwan University Hospital

Unknown

IGFBP-3 in Ovarian Cancer Invasion

Ovarian Carcinoma

Taiwan
AbbVie

Withdrawn

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Cancer - Ovarian
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer (ICEBERG 2)

Ovarian Neoplasm

United States, Spain, Australia, Germany, Sweden
National Cancer Institute (NCI)

Completed

A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse)

Ovarian Neoplasm

United States
National Cancer Institute (NCI)

Completed

A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer

Ovarian Neoplasm

United States
University Health Network, Toronto

Completed

18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)

Stage IV Ovarian Cancer | Stage III Ovarian Cancer

Canada
Yonsei University
National Cancer Center, Korea; Samsung Medical Center; AstraZeneca; Seoul National... and other collaborators

Unknown

A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) (KGOG3046)

Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV

Korea, Republic of
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Gastrointestinal Complication and other conditions

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery

Ovarian Cancer | Fallopian Tube Cancer | Fallopian Tube Carcinoma | Peritoneal Carcinoma | Ovarian Carcinoma | Peritoneal Cancer | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Fallopian Tube Cancer Stage IIIC | Fallopian Tube Cancer Stage IV

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary... and other conditions

United States
Shattuck Labs, Inc.

Enrolling by invitation

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma

United States, United Kingdom, Spain, Canada
Grupo Español de Investigación en Cáncer de Ovario
Roche Pharma AG

Terminated

Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin (NOVA)

Cancer, Ovarian

Spain
Imperial College London
GlaxoSmithKline

Completed

[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer (PAZPET-1)

Ovarian Neoplasm

United Kingdom
Genelux Corporation
GOG Foundation

Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Platinum-refractory Ovarian Cancer | Primary Peritoneal Cancer | High-grade Serous Ovarian Cancer | Endometrioid Ovarian Cancer | Ovarian Clear Cell Carcinoma

United States
Fengzhi Feng

Recruiting

Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors

Recurrent Ovarian Carcinoma

China
University of Aarhus
Department of Clinical Medicine, Aarhus University; Department of Gynaecology... and other collaborators

Recruiting

Improved Diagnosis of Ovarian Cancer

Ovarian Cysts | Ovarian Neoplasms | Ovarian Cancer | Adnexal Mass | Adnexal Lesion | Adnexal Carcinoma | Adnexal Neoplasm

Denmark
Cybrexa Therapeutics

Not yet recruiting

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Platinum-resistant Ovarian Cancer | Refractory Ovarian Carcinoma
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Active, not recruiting

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian Neoplasms | Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

United States, Netherlands, Spain, Finland, Italy, Poland, Belgium, Canada, France, Germany, Romania, Ukraine, Norway, United Kingdom, Israel, Greece, Denmark, Belarus, Czechia
Sun Yat-sen University
Hutchmed

Recruiting

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer | Ovarian Carcinoma | Fallopian Tube Carcinosarcoma

China
iOMEDICO AG

Recruiting

Registry Platform Ovarian and Endometrial Cancer (SMARAGD)

Carcinoma | Ovarian Cancer | Endometrial Neoplasms | Endometrial Cancer | Ovary Neoplasm | Neoplasm, Ovarian | Carcinoma, Ovarian

Germany
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Intra-operative Imaging in Women With Ovarian Cancer

Ovarian Cancer | Ovarian Carcinoma

United States
Shanghai Gynecologic Oncology Group
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Obstetrics... and other collaborators

Not yet recruiting

Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

China
Instituto Nacional de Cancerologia de Mexico

Recruiting

HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy

Ovarian Cancer | Chemotherapy Effect | HPEC | Women's Health: Neoplasm of Ovary

Mexico
ImmunoGen, Inc.
Gynecologic Oncology Group

Completed

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

United States, France, Canada, Spain, Switzerland, Belgium, Italy, United Kingdom, Ireland, Russian Federation, Bosnia and Herzegovina, Czechia, Serbia
The University of Texas Health Science Center at...

Completed

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer (ONTAK)

Epithelial Ovarian Cancer | Fallopian Tube Carcinoma | Extraovarian Peritoneal Cancer

United States
AGO Study Group

Completed

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Ovarian Cancer | Peritoneal Cancer | Cancer of the Fallopian Tube

Germany
GlaxoSmithKline

Completed

Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors

Cancer | Epithelial Ovarian Cancer | Tumor | Primary Peritoneal Carcinoma | Neoplasms, Ovarian | Uterine Disease | Cervix Diseases

France, Germany
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
National Cancer Institute (NCI)

Completed

EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer

Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Stage IV Endometrial Carcinoma | Stage I Ovarian Epithelial Cancer | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Stage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer

United States, Canada
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery

Recurrent Ovarian Carcinoma | Recurrent Uterine Corpus Carcinoma | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Uterine Corpus Cancer AJCC v7 | Stage IV Ovarian Cancer AJCC v6 and v7 | Stage IV Uterine Corpus Cancer AJCC v7 | Adult Solid Neoplasm

Canada
National Cancer Institute (NCI)

Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Ovarian Carcinoma | Pancreatic Carcinoma | Prostate Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer

Ovarian Carcinoma | Malignant Ovarian Neoplasm

United States
Ling-Ying Wu

Not yet recruiting

Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (RENI-1)

Epithelial Ovarian Cancer
AGO Research GmbH

Recruiting

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC (WoO)

Epithelial Ovarian Cancer

Germany
Allarity Therapeutics
Amarex Clinical Research; Alcedis GmbH

Recruiting

Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® (PREDICT 2X-121)

Advanced Ovarian Cancer

United Kingdom, United States
Groupe Hospitalier Diaconesses Croix Saint-Simon
GERCOR - Multidisciplinary Oncology Cooperative Group

Recruiting

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer (CHIMOVIP)

Ovarian Cancer, Epithelial

France
Grupo Español de Investigación en Cáncer de Ovario
AstraZeneca

Completed

Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin (ROLANDO)

Advanced Ovarian Cancer

Spain
Opna-IO LLC

Terminated

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

Epithelial Ovarian Cancer | Gynecologic Neoplasms

United States, Canada
Shanghai East Hospital
Anhui Provincial Hospital; Nanjing Legend Biotech Co.; East Clinical Center of...

Terminated

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer

Epithelial Ovarian Cancer

China
Translational Research in Oncology
Celgene

Terminated

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

Epithelial Ovarian Cancer

United States

Clinical Trials on Ovarian Seromucinous Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations